RO7296682
- Generic Name
- RO7296682
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- HV8TQI2IKP
- Background
RO7296682 is a monoclonal antibody against CD25 (IL-2R alpha) expressed on tumour-infiltrating regulatory T (T) cells. RO7296682 is under investigation in clinical trial NCT04642365 (A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT04642365
- Locations
- π§πͺ
Cliniques Universitaires St-Luc, Bruxelles, Belgium
π¨π¦The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
π¦πΊPeter Maccallum Cancer Institute; Clinical Trial Unit, Melbourne, Victoria, Australia
A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 76
- Registration Number
- NCT04158583
- Locations
- π§πͺ
Cliniques Universitaires St-Luc, Bruxelles, Belgium
π¨π¦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
π¨π¦The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.